Pipeline04

Our multi-specific immuno-oncology drug ND021 holds the promise to outperform first-generation checkpoint modulators in terms of safety and efficacy.

Partnered Regionally
Discovery
Preclincal PoC
IND-enabling studies
Phase I
Partner
NM21-1480 (αPD-L1/4-1BB/hSA) Oncology
NM26-2198 (multi-specific) INFLAMMATION
NM28-2746 (biMSLN/CD3/hSA)
Fully Owned by Numab
NM32-2668 (aROR1/CD3/hSA) Oncology
Partnered Globally
Research
Development
Partner
ND009 (αTNF) IBD
ND023 (multi-specific) Oncology
ND034-38 (multi-specific) Oncology
ND039 (multi-specific) Oncology
ND040-42 (multi-specific) Oncology

NM21-1480 – Immuno-oncology

NM26-2198 – Inflammation

NM32-2668 – Immuno-oncology

NM28-2746 – Immuno-oncology

Multispecific Immuno-Oncology Products

Patient Information

NM21-1480 – Immuno-oncology

NM21-1480 is a next-generation multi-specific cancer therapeutic that simultaneously targets the tumor-immunity suppressive PD(L)-1 pathway and the tumor-immunity stimulatory 4-1BB/CD137 pathway. Targeting these two clinically validated pathways in a combinatorial approach is expected to provide patients suffering from a broad range of cancer types with a unique novel treatment opportunity characterized by an improved benefit-to-risk profile as compared to current standard of care as well as other combinatorial immunotherapy approaches currently in clinical development. The differentiating profile of NM21-1480 is based on its molecular design as a monovalent trispecific antibody fragment aimed at highly effective, while only local activation of a tumor-directed specific immune response. NM21-1480 is currently being tested in a phase 1/2 clinical study (NCT04442126) in patients with advanced solid tumors. Numab develops this therapy together with its Chinese partner CStone Pharmaceuticals.

Poster presentation at AACR Annual Meeting 2020

Poster presentation at AACR Annual Meeting 2022

NM21-1480: A novel tri-specific antibody for oncology
Learn more about its unique mode-of-action

video numab
×

NM26-2198 – Inflammation

NM26-2198 is a bispecific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis, or AD. NM26-2198 is designed to prevent IL-4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis. The targeting of the IL-4/IL-13 pathway is well established for the treatment of AD and other inflammatory diseases, with therapies such as dupilumab, marketed as Dupixent, demonstrating both clinical efficacy and the size of the potential market opportunity. We believe that adding IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade could enable a faster onset of action and improved efficacy compared to the current standard of care in AD, together with convenient subcutaneous administration. Numab develops this program together with its Japanese partner Kaken Pharmaceutical Co., Ltd.

Poster presentation at EADV Congress 2022

NM32-2668 – Immuno-oncology

NM32-2668 is a tri-specific anti-ROR1/CD3/HSA antibody based on our scMATCH3 format. NM32-2668 induces T cell-mediated lysis of tumors expressing Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). Binding to human serum albumin (HSA) prolongs the half-life of the molecule in circulation and supports a convenient dosing scheme. ROR1 is overexpressed on a variety of difficult to treat tumors, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), triple-negative breast cancer (TNBC), lung cancer, and ovarian cancer. ROR1-expressing hematologic and solid tumors display a high potential for self-renewal, increased survival, and migration, and are associated with poor outcomes.

Poster presentation at SITC Annual Meeting 2021

NM28-2746 – Immuno-oncology

NM28 consists of four stabilized and humanized antibody variable domain fragments directed against MSLN, CD3, and human serum albumin (HSA). MSLN is commonly expressed in a variety of tumor cells, including mesothelioma, lung, biliary, ovarian, breast, and pancreatic cancer. NM28 is designed to be resistant to the scavenging effect of soluble MSLN shed from tumor cells to improve efficacy, and to discriminate between tumor cells and MSLN-expressing normal cells to improve safety when compared to monovalent T cell engaging approaches targeting MSLN. Numab develops this therapy together with its Chinese partners 3SBio / Sunshine Guojian.

Poster presentation at SITC Annual Meeting 2020

Poster presentation at AACR Annual Meeting 2022

Multispecific Immuno-Oncology Products

Numab is developing multiple proprietary immuno-oncology programs utilizing our versatile, multi-specific MATCH platform. We are combining immune effector functions, immune-checkpoint antagonism, and cancer-specific targeting to create highly innovative, multi-functional drug candidates designed to bring significant improvement to the lives of cancer patients.

Newsletter Sign Up

Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept